<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04824885</url>
  </required_header>
  <id_info>
    <org_study_id>AOI 2019 ANIORT</org_study_id>
    <secondary_id>2020-A00678-31</secondary_id>
    <nct_id>NCT04824885</nct_id>
  </id_info>
  <brief_title>Study of a Dialysate Without Acetate on Protein Energy Wasting Syndrome in Chronic Hemodialysis Patient (EASY)</brief_title>
  <acronym>EASY</acronym>
  <official_title>Study of a Dialysate Without Acetate on Protein Energy Wasting Syndrome in Chronic Hemodialysis Patient</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Clermont-Ferrand</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This work aims to study the effect of an acetate-free dialysate on protein-energy wasting&#xD;
      syndrome in patients with chronic hemodialysis renal failure, in comparison to a conventional&#xD;
      dialysate with acetate. The hypothesis is that a dialysate without acetate would improve&#xD;
      patients nutritional status&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The dialysate usually used at the Clermont Ferrand CHU dialysis center is a dialysate&#xD;
      containing acetate After inclusion, patients will be randomly divided into two groups.&#xD;
      Patients in group 1 will first be treated with the acetate-free dialysate (A-D) for 6 months&#xD;
      and then the acetate-containing dialysate (A + D) for 6 months. Group 2 patients will&#xD;
      continue on the usual dialysate (A + D) for 6 months and then switch to A-D dialysate for the&#xD;
      next 6 months. Patients will be blinded from study treatment.&#xD;
&#xD;
      Patients will be followed for 1 year.&#xD;
&#xD;
      A the beginning then every 3 months will be carried out:&#xD;
&#xD;
        -  A measurement of body composition by multi-frequency bioimpedancemetry&#xD;
&#xD;
        -  A measurement of the gripping force by a dynamometer (hand grip force )&#xD;
&#xD;
        -  A 4-meter walk test&#xD;
&#xD;
        -  A SARC-F Sarcopenia Assessment Questionnaire A blood test for the usual biological&#xD;
           analyzes carried out as part of the recommendations for monitoring patients on&#xD;
           hemodialysis will be carried out every month.&#xD;
&#xD;
      An additional blood sample (5.5 mL) for quantification of the levels of expression of&#xD;
      potential blood biomarkers of muscle condition will be taken initially, at 6 months and at 12&#xD;
      months (i.e. 16.5 mL more compared to current practice). ).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">February 2024</completion_date>
  <primary_completion_date type="Anticipated">November 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>prealbumin</measure>
    <time_frame>change at 6 months from the start of Acetate free or acetate containing dialysate</time_frame>
    <description>biochemical measurement</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Muscle mass</measure>
    <time_frame>change at 6 months from the start of acetate free or acetate containing dialysate</time_frame>
    <description>Lean Tissue Index or LTI from the spectral analysis of body bioimpedance according to the model of Chamney et al, creatine index according Desmeules et al</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle performance</measure>
    <time_frame>change at 6 months from the start of acetate free or acetate containing dialysate</time_frame>
    <description>meter walk test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle performance with hand grip test</measure>
    <time_frame>change at 6 months from the start of acetate free or acetate containing dialysate</time_frame>
    <description>hand grip test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SARC-F</measure>
    <time_frame>change at 6 months from the start of acetate free or acetate containing dialysate</time_frame>
    <description>Result of SARC-F survey</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>muscle biomarkers</measure>
    <time_frame>Month 6</time_frame>
    <description>blood RNA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>muscle biomarkers</measure>
    <time_frame>Year 1</time_frame>
    <description>blood RNA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality</measure>
    <time_frame>Year 1</time_frame>
    <description>Time to death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>morbidity</measure>
    <time_frame>Year 1</time_frame>
    <description>Time to cardiovascular events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>End Stage Renal Disease</condition>
  <condition>Hemodialysis</condition>
  <arm_group>
    <arm_group_label>Acetate free then acetate containing dialysate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in group 1 will first be treated with the acetate-free dialysate (A-D) for 6 months and then the acetate-containing dialysate (A + D) for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acetate containing dialysate then acetate free dialysate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 2 patients will continue on the usual dialysate (A + D) for 6 months and then switch to A-D dialysate for the next 6 months. Patients will be blinded from study treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Chlorhydric acid based acid concentrate for bicarbonate hemodialysis (medical device)</intervention_name>
    <description>usual dialysate (A + D) for 6 months and then switch to A-D dialysate for the next 6 months</description>
    <arm_group_label>Acetate containing dialysate then acetate free dialysate</arm_group_label>
    <arm_group_label>Acetate free then acetate containing dialysate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Major patient;&#xD;
&#xD;
          -  Man or woman ;&#xD;
&#xD;
          -  Treated with intermittent hemodialysis for chronic renal failure;&#xD;
&#xD;
          -  Affiliated with a social security scheme;&#xD;
&#xD;
          -  Having given a signed agreement after detailed explanation of the protocol on the&#xD;
             basis of the information sheet and likely to comply with it&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with lower limb amputation more proximal than a transmetatarsal amputation&#xD;
             (invalidity of the model for estimating body composition by BCM in this situation)&#xD;
&#xD;
          -  Acute event in the 3 months preceding inclusion (infection, surgery).&#xD;
&#xD;
          -  Having a neuromuscular pathology responsible for a motor deficit.&#xD;
&#xD;
          -  Whose life expectancy does not exceed 6 months&#xD;
&#xD;
          -  With a psychiatric pathology or cognitive impairment rendering him unable to give&#xD;
             informed consent&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Patient under guardianship, curatorship or legal protection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julien Aniort</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Clermont-Ferrand</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lise LACLAUTRE</last_name>
    <phone>+33473754963</phone>
    <email>promo_interne_drci@chu-clermontferrand.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Lise Laclautre</last_name>
      <phone>+33473754963</phone>
      <email>promo_interne_drci@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Julien Aniort</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 23, 2021</study_first_submitted>
  <study_first_submitted_qc>March 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2021</study_first_posted>
  <last_update_submitted>March 29, 2021</last_update_submitted>
  <last_update_submitted_qc>March 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acetate free dialysate</keyword>
  <keyword>hemodialysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Wasting Syndrome</mesh_term>
    <mesh_term>Cachexia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

